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Adequate blood supply is a prerequisite in the pathogenesis of solid malignancies. As a result, depriving a tumour from its oxygen and
nutrients, either by preventing the formation of new vessels, or by disrupting vessels already present in the tumour, appears to be an
effective treatment modality in oncology. Given the mechanism by which these agents exert their anti-tumour activity together with
the crucial role of tumour vasculature in the pathogenesis of tumours, there is a great need for markers properly reflecting its impact.
Circulating endothelial cells (CEC), which are thought to derive from damaged vasculature, may be such a marker. Appropriate
enumeration of these cells appears to be a technical challenge. Nevertheless, first studies using validated CEC assays have shown that
CEC numbers in patients with advanced malignancies are elevated compared to healthy controls making CEC a potential tool for
among other establishing prognosis and therapy-induced effects. In this review, we will address the possible clinical applications of
CEC detection in oncology, as well as the pitfalls encountered in this process.
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Angiogenesis is thought to be an absolute prerequisite for the
growth and dissemination of malignant tumours. When a tumour
reaches a size of 1–2mm
3, its microenvironment can no longer
provide the required amount of nutrients and oxygen by diffusion.
The resulting cellular hypoxia initiates a response in malignant
cells: the so-called ‘angiogenic switch’ (Naumov et al, 2006). By
upregulating the expression of proangiogenic proteins, the tumour
induces sprouting of pre-existing capillaries, which result in the
formation of new vessels.
The pivotal role of angiogenesis in tumour growth prompted the
development of several agents targeting receptors or signal
transduction pathways involved in angiogenesis. Based on data
from randomised clinical trials, the benefit of compounds that
inhibit angiogenesis has already been demonstrated in several
types of cancer, including metastatic colon carcinoma (Kabbinavar
et al, 2003), renal cell carcinoma (Motzer et al, 2007), and non-
small lung cell carcinoma (Sandler et al, 2006). In addition to these
drugs inhibiting angiogenesis, another class of anticancer drugs,
vascular disrupting agents (VDAs), has recently been developed
and is designed to target already established tumour vasculature.
Clinical studies exploring the latter drugs are currently ongoing.
Given the important role of angiogenesis in oncology in terms
of pathogenesis as well as being a target for treatment, there is an
increasing need for markers that accurately reflect effects
impacting tumour vasculature. A promising candidate to serve
as such a marker is the enumeration of circulating endothelial cells
(CEC). CEC are mature endothelial cells, sloughed off the vessel
wall as a result of vascular insults. Their number in peripheral
blood is considered to reflect the extent of vascular damage in
patients with vasculopathies. Recently, several assays for their
detection and quantification have been developed. Although
consensus on the phenotypic definition of CEC as well as on the
optimal enumeration technique is still lacking, the number of
clinical studies assessing CEC in cancer patients is rapidly
expanding. Several studies on CEC also incorporate a strategy to
enumerate endothelial progenitor cells (EPC), which, in contrast
to CEC, are thought to originate from the bone marrow and to
contribute actively to angiogenesis. A study by Lyden showed in a
murine model that, all tumour vessel endothelial cells were
bone marrow-derived (Lyden et al, 2001), and similar observations
were done in humans (Peters et al, 2005), stressing the importance
of EPC in angiogenesis. However, as the frequency of EPC in blood
is suggested to be several times lower than those of CEC,
while additionally, their exact phenotype has not been elucidated,
it is very difficult to reliably detect and enumerate EPC by
currently available assays. EPC are therefore not included in this
article.
This review provides an overview of the uses of CEC as surrogate
marker for vascular damage in oncology, in particular technical
issues concerning their detection, its potential applications, and
results from clinical studies obtained so far.
TECHNICAL ISSUES IN CEC ENUMERATION
Currently, there are several assays described for the detection and
enumeration of CEC. All these assays have to deal with the low
number of CEC in peripheral blood, (typically 0–20CEC per ml in
healthy donors) rendering such assays highly susceptible to errors
in sampling, preparation, and analysis. For instance, several
groups have demonstrated the negative impact of venipuncture,
as traumatically detached CEC contribute significantly to CEC
counts (Goon et al, 2006; Rowand et al, 2007). Because of this low
number, enrichment steps are applied in several approaches,
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actual CEC number. Next to proper sampling, thorough analysis
of enrichment efficacy, reported in terms of purity and recovery
is therefore mandatory before using such assays based on
enrichment in the clinic. The EUROCEC network has provided
useful suggestions on how such a validation might be performed in
practise (www.eurocec.com)(Woywodt et al, 2006).
Of key importance for proper detection and enumeration of CEC
is the use of specific markers. However, the endothelium is a highly
dynamic structure, closely involved in haemostasis, inflammation,
regulation of vascular tonus, and angiogenesis. This dynamic
process is accompanied by changing immunophenotype of
endothelial cells that may largely account for the large number
of different CEC phenotypes reported in literature. For enumeration
of the total CEC number, and not a particular subpopulation, it
is necessary to identify markers that are specific for and are
constantly expressed by all CEC. Currently, no marker is
considered to meet these criteria. Consequently, assays rely on
multiple characteristics to define CEC. The majority of current
assays define CEC as being positive for the CD146 antigen, present
on endothelial cells, but also on a subset of activated T-cells, and
melanomas (Elshal et al, 2005). Table 1 provides an overview of
markers frequently used in CEC assays. As the different reported
phenotypes render it impossible to compare results between
various studies, consensus on a common endothelial cell
phenotype is a key issue.
Another mandatory step in the development of CEC assays is the
validation of the true endothelial origin of cells designated CEC by
that assay. For this purpose, several unique features of endothelial
cells can be used. These include uptake of Ulex Europaeus Lectin-1,
or UEA-1 (Goon et al, 2006) or the ability of CEC to scavenge
acetylated low-density lipoproteins, which can be visualised when
labelled with 1,10-dioctadecyl-3,3,30,30-tetramethyl-indocarbocyanine
perchlorate (Dil Ac-LDL) (Voyta et al, 1984). In addition,
immunohistochemistry or immunofluorescence can be used to
demonstrate the presence of von Willebrand factor (VWF), or
other endothelial surface markers (Table 1).
Another means of validation is through gene expression
profiling assessing whether or not expression of endothelial
genes such as vascular endothelial cadherin (VE-cadherin),
is present in the population of cells designated as CEC
(Smirnov et al, 2006).
AVAILABLE ASSAYS
Manual immunomagnetic isolation
The most widely used method to isolate CEC, is by the use of
magnetic beads coupled to a monoclonal antibody (mAb) targeting
CD146, as first described by Dignat-George (George et al, 1992).
After isolation, additional techniques, such as flow cytometry or
microscopic analysis, are used to identify CEC based on morpho-
logical or immunophenotypical criteria. A major advantage of this
technique is that it permits visual identification of CEC, which
allows them to be discriminated from endothelial micro particles,
anuclear cells, and cellular conglomerates. However, manual bead-
based isolation has several shortcomings, especially with regard to
large monitoring studies. It is labour-intensive, requires a high
level of operator skills, and requires additional steps to positively
identify CEC, which make them unsuitable for high throughput
monitoring. Furthermore, magnetic enrichment may give rise to an
underestimation of the actual number of CEC. As CD146
expression on CEC is lower than on the HUVEC used to test
assay recovery, its expression by CEC might be insufficient to bind
to magnetic beads.
Automated isolation and staining
A variant on techniques applying a manual immunomagnetic
enrichment step, is the CellTracks AutoPrep and CellTracks
Analyzer II System (Immunicon Corp, Huntington Valley, PA,
USA), initially designed to detect circulating tumour cells. As with
manual immunomagnetic isolation, cells are isolated by CD146-
coupled ferrofluids, with the main difference being that the
CellTracks System is fully automated, and is therefore not operator
dependent. After isolation, the suspension of CD146
þ cells is
stained with (i) 40,6-diamidino-2-phenylindole (DAPI) to identify
nucleated cells, (ii) CD105, fairly unique on endothelial cells, and
(iii) CD45, to exclude CD146-expressing T cells. The enriched and
stained sample is dispensed in a magnetic cartridge to form a
monolayer of cells, which is scanned by the CellTracks Analyzer II
System. The generated images are evaluated for CEC by visual
inspection, in which CEC are defined as DAPI
þ, CD105
þ,
CD146
þ, CD45
  (Rowand et al, 2007). The endothelial feature of
the cells meeting these phenotypic criteria was further demon-
Table 1 Markers used in CEC assays
Marker Description Subtype association Expression level Coexpression References
CD31 PECAM-1 Pan-endothelial ++
a P, Pan-leukocyte (Beerepoot et al, 2004)
CD34 Stem cell marker Pan-endothelial ++
a S (Furstenberger et al, 2006)
CD36 Collagen receptor I Micro vascular +
a P, E, M, D (Moroni et al, 2005)
CD54 ICAM-1 Inflammation +
a L, M (Dixon et al, 2004)
CD62-E E-selectin Inflammation ++ — (Dixon et al, 2004)
CD62-P P-selectin Inflammation + P (Corcoran et al, 2006)
CD105 Endoglin Angiogenesis, malignant ++
a S, M
b (Rowand et al, 2007)
CD106 VCAM-1 Inflammation, malignant +
a — (Dixon et al, 2004)
CD137 ILA/4 Malignant + L
b, D (Seaman et al, 2007)
CD144 VE-cadherin Pan-endothelial +
a — (Smirnov et al, 2006)
CD146 MelCAM Pan-endothelial ++
a L
b (Dignat-George et al, 2007)
CD202b Tie-2 Angiogenesis (+)
a — (Smirnov et al, 2006)
CD276 B7-H3 Malignant + D, M
b (Seaman et al, 2007)
CD309 VEGFR-2 Angiogenesis (+)
a S (Beerepoot et al, 2004)
VWF Pan-endothelial ++
a P (Woywodt et al, 2006)
UEA-1 Pan-endothelial ++ — (Woywodt et al, 2006)
DiL-AcLDL Pan-endothelial ++ — (Voyta et al, 1984)
PECAM-1¼platelet/endothelial cell adhesion molecule 1, ICAM-1¼intracellular adhesion molecule 1, VCAM-1¼vascular cellular adhesion molecule 1,
ILA/4¼inducible by lymphocyte activation /4, MelCAM¼melanoma-associated cellular adhesion molecule, Tie-2¼angiopoietin-1, 2, 4 receptor, B7-H3¼B7 homologue 3,
VEGFR-2¼vascular endothelial growth factor receptor 2. S¼hematopoietic stem cells, L¼lymphocytes, P¼platelets, M¼monocytes, E¼erythrocytes, D¼dendritic cells.
Expression levels: ++¼strong, +¼moderate, (+)¼weak.
aIndicates data based on flow cytometric results from the authors.
bIndicates presence on activated cells.
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demonstrated the presence of endothelial markers (Smirnov
et al, 2006). Drawbacks of this method are the costly equipment
and reagents, while assay customisation is not possible. Also, the
maximum number of only eight samples that can be analysed in a
single run, combined with the relative long duration of a complete
run (approximately 4h), limits high throughput analysis.
Flow cytometry
Flow cytometry is a widely accepted tool for immunophenotyping
of cells. A cocktail of fluorochrome-labelled mAb is used to
identify CEC, allowing a highly specific definition of CEC, and
possibly, the identification of endothelial cell subsets such as EPC.
Another benefit of flow cytometry is, that by multi-colour staining
cells with an immunophenotypical overlap with CEC, such as
endothelial micro particles and platelets, can be excluded from
evaluation, which increases specificity. However, flow cytometry
assays in whole blood are at risk to overestimate CEC by
enumerating false-positive cells. A well-known cause of false
positivity is non-specific antibody-binding. Non-specific-binding
can be the result of Fc receptor-binding, binding to dead cells, or
by improper use of reagents. A recent study clearly showed that the
exceptionally high CEC counts found with a commonly applied
flow cytometry based assay (Mancuso et al, 2001), were due to the
fact that the majority of the cells designated CEC were in fact large
platelets (Strijbos et al, 2007).
As a result of improper titration of the CD146mAb cells with a
CD45
dim, CD31
þ phenotype stained positively for this antigen,
suggesting that CEC were enumerated. Such problems can be
prevented through staining whole blood rather than a cell
suspension, or through the use of a blocking reagent, by which
Fc receptors are kept saturated and non-specific binding is
prevented. Furthermore, addition of a real-time viability stain,
such as 7-aminoactinomycin D or propidium iodide, allows the
exclusion of dead cells. Next to interference by non-specific
antibody-binding, false positivity can also result from specific-
binding to soluble forms of the antigen. Many endothelial surface
antigens such as sCD144, and sCD146 are secreted, and their
uptake by platelet aggregates can result in positivity. An effective
strategy for excluding platelets, aggregates and endothelial micro
particles from analysis is by using a DNA-specific stain, such as
(DAPI) or 1,5-bis[2-(di-methylamino) ethyl]amino-4, 8-dihydroxy-
anthracene-9,10-dione (DRAQ5).
Recently, absolute CEC counts obtained by both magnetic
isolation and flow cytometry assays were compared (Goon et al,
2006). The reasonable agreement in CEC counts between both
methods, in combination with an established CEC phenotype
(i.e. CD34
þ, CD146
þ, CD45
 ), is suggestive that actual CEC
counts are being approached by this flow cytometry assay.
However, isolation and validation as done on the magnetically
isolated cells (Rowand et al, 2007), was not performed on the CEC
as defined by Goon et al (2006).
CLINICAL RESULTS
Although a large number of studies on CEC in cancer patients have
been published, many of these studies rely on a flow cytometric
approach, which defines CEC as being CD45
 , CD31
þ, and
CD146
þ. Although this is a generally accepted CEC immunopheno-
type, reports are currently not available in which the endothelial
origin of cells enumerated by those assays has been demonstrated
unambiguously (Duda et al, 2006; Mancuso et al, 2006). As a result,
studies on CEC that are in our opinion reliable, are scarce: only
three studies are currently available, all based on CD146 driven
magnetic isolation of CEC (Beerepoot et al, 2004; Woywodt et al,
2006; Rowand et al, 2007). In the first study, CEC were enumerated
by magnetic isolation, followed by visual analysis of CD31, CD309
and VWF expression, determined by immunofluorescence. CEC
numbers in cancer patients (n¼146, mean CEC 399±36ml
 1)
were found to be increased 3.3 fold when compared to healthy
controls (n¼46, mean CEC 121±16ml
 1). Further analysis of
CEC numbers in cancer patients, demonstrated significantly higher
CEC in patients with progressive disease vs those with stable
disease (95 patients, 438±65 CEC per ml and 17 patients, 179±61
CEC per ml, respectively), whereas no difference was seen between
patients with stable disease and healthy donors (Beerepoot et al,
2004). The increased CEC count in cancer patients was confirmed
in a study of Rowand using the CellTracks System. Cells were
isolated by automated CD146 driven magnetic isolation, and assay
accuracy, sensitivity, linearity and precision were assessed, Here-
after, nucleated (DAPI
þ) cells, expressing CD105 but lacking CD45
were enumerated in 249 healthy donors and 206 patients with
metastatic cancer (Rowand et al, 2007). The observed mean CEC
count of 21 in healthy controls is comparable by those found by
the EUROCEC assay. Strikingly, the number of CEC reported in
healthy donors was 10-fold lower when compared to those
reported by Beerepoot, namely 0–20ml
 1 (Rowand et al, 2007).
Both groups isolate CEC using beads targeting CD146, but
Beerepoot uses CD31, CD309 and VWF, rather than CD105 to
confirm the endothelial origin of cells. Where CD31 and VWF are
considered to be pan-endothelial cell markers, CD105 is expressed
predominantly on proliferative and/or malignant CEC. Given its
high recovery and reproducibility and extensive validation, we
favour the CellTracks assay for isolating CEC.
POTENTIAL APPLICATIONS IN ONCOLOGY
Provided that an adequately validated, sensitive and specific assay
is used, the detection and enumeration of CEC in patients with
solid malignancies offer a wide spectrum of potential applications.
CEC: marker for establishing prognosis and for follow-up?
The observation that advanced cancer patients have higher CEC
counts than healthy controls (Beerepoot et al, 2004; Rowand et al,
2007), whereas patients with stable disease and healthy individuals
have similar numbers (Beerepoot et al, 2004), may imply that CEC
enumeration may be used for prognosis and during follow-up in
cancer patients. Obviously, verification of this statement would
require studies in which large numbers of patients are included
with enumeration of CEC at baseline and during follow-up.
CEC: marker for response to treatment?
Classic methods to establish antitumour effects of systemic agents,
which rely on assessing changes in tumour size by radiological
assessments, are no longer sufficient. This holds true not only
when using conventional chemotherapeutic drugs, but in parti-
cular when angiogenesis inhibitors are applied. In several
randomised trials exploring such drugs, enhanced progression-
free periods were observed, yet the response rates as defined by
RECIST, were minimal (Yang et al, 2003). Such findings emphasize
the limitations of conventional imaging, as well as the need to
incorporate novel, sensitive indicators of response. The increase in
CEC numbers in mice stimulated with VEGF, and the consecutive
decrease of these numbers after treatment with the angiogenesis
inhibitor endostatin (Schuch et al, 2003), are suggestive of a
possible role for CEC in monitoring response to treatment when
using agents targeting the VEGF-VEGFR pathway. Recently, a
xenograft prostate cancer model showed that an increase in
apoptotic CEC after treatment with thalidomide and docetaxel, was
predictive for response to treatment (Li et al, 2008). However, as
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to confirm these findings using different, validated techniques.
CEC: guideline for optimal drug dosing?
Nowadays, it is increasingly recognised that the recommended
dose for further exploration of a drug should be the optimal
biological drug dose (OBD) rather than the MTD. The OBD is
defined as the dose that is feasible to be applied in humans and
yields biological effects. Changes in CEC counts after dose
escalation might provide useful insights in establishing the OBD
when assessing agents targeting vasculature such as VDA or
angiogenesis inhibitors. A recent study by Celik et al (2005)
reports a 50% decrease in CEC in tumour-bearing mice treated
with endostatin. The decrease in CEC showed a clear U-shaped
dose relation. The optimum dose, determined by assessment of
tumour micro vessel density and analysis of tumour blood flow,
resulted in the largest decrease in CEC numbers, whereas under- or
over treatment resulted in a diminished decrease or even increase
in CECs, suggesting a rationale for using CEC as guideline for
optimum drug dosing. However, whether this holds true for
humans, and for anti-angiogenic drugs other than endostatin,
remains to be established.
CEC: towards identification of new targets in oncology?
One of the major advances in the management of cancer in the last
decades is the introduction of targeted therapy. By identifying
tumour factors that play a crucial role in the pathogenesis of a
disease, an avalanche of new targets for therapy has been
identified. Examination of endothelial cells from tumour vascu-
lature, may result in the identification of antigens specific for
malignant angiogenesis, such as the recently identified H3
homologue of the costimulatory molecule B7 (CD276) (Seaman
et al, 2007), and allow the development of agents selectively
targeting tumour vasculature.
CEC: marker for vascular toxicity?
With better treatment outcomes for some patient populations with
advanced malignancies, there is growing interest for long-term
side effects of antitumour therapies. An increased incidence of
cardiovascular events has emerged as one of the most important
long-term untoward sequelae. For example, patients treated with
chemotherapy for advanced germ-cell cancer have a 2–7-fold
increased risk for cardiovascular events when compared to the
general population (Meinardi et al, 2000). Although the exact
mechanism of this increased risk is unknown, in vitro data suggest
that cytotoxic agents directly cause endothelial damage. Frequently
used agents such as cisplatin, bleomycin and etoposide, can cause
thickening of the carotid artery intima, Raynaud’s phenomenon,
and an increase in plasma C-reactive protein (CRP), VWF and
PAI-1, all associated with endothelial dysfunction (Nuver et al,
2005). Monitoring biomarkers of endothelial dysfunction or
damage such as CEC levels, both during and after treatment might
provide more insight into the vascular toxicity profile of
chemotherapeutic agents. On the basis of such data, less vasotoxic
treatments with equivalent antitumour activity would be
warranted, especially for patients for whom treatment is likely to
result in long-term survival, such as in germ cell cancers,
childhood lymphoblastic leukaemia and lymphoma subtypes. A
recent phase I study with the protein kinase b C inhibitor
enzastaurin (Rademaker-Lakhai et al, 2007), in which CEC were
enumerated by immunomagnetic isolation, did not find an effect
of enzastaurin on CEC numbers. In contrast, a study on the VDA
ZD6126 demonstrated a significant increase in immunomagneti-
cally isolated CEC 2–8h after infusion (Beerepoot et al, 2004).
Given the presumed mechanism of action of VDAs, this finding
strongly suggests that CEC serves as a marker to assess vascular
toxicity of drugs.
CONCLUSIONS
In view of the growing recognised role of angiogenesis in oncology,
and the integration of drugs targeting tumour vasculature,
biomarkers that enable monitoring effects on vasculature are
urgently needed. Many soluble markers, including VWF and
thrombomodulin have been proposed as such markers. However,
most of these are acute phase products and therefore susceptible to
interference by other events frequently encountered in cancer
patients such as infection. By contrast, monitoring CEC appears an
attractive candidate. Several techniques have been developed to
detect and enumerate CEC, but the lack of consensus on the
phenotype of CEC, as well as their low numbers in blood, have
resulted in conflicting results and have severely hindered progress
in this important field. Providing a clear definition of CEC together
with careful confirmation and validation that cell population
designated ‘circulating endothelial cells’ are indeed CEC, are the
most important issues that need to be addressed. To overcome
these issues, suggestions on phenotype and detection strategy have
been provided by the EUROCEC network (Woywodt et al, 2006).
Despite these problems, validated assays enabling the proper
enumeration of CEC are since recently available and the first
results have revealed that patients with advanced cancer have
indeed higher levels than healthy controls. In theory, there are
many potential applications for the assessment of CEC counts in
patients with solid malignancies including establishing prognosis
and therapy-induced effects, but whether or not CEC can actually
be used for these purposes is currently the subject of clinical
studies. So only time will tell whether CEC can fulfil its promise as
a biomarker in clinical oncology.
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